SAN DIEGO, Dec 6 (Bernama-GLOBE NEWSWIRE) — For twenty-five years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. The LeukoStrat® CDx FLT3 Mutation Assay may now be used as an aid in the assessment of AML patients for treatment with XOSPATA® (gilteritinib) in Europe. FLT3 mutation must be confirmed with a validated test, such as the LeukoStrat CDx FLT3 Mutation Assay, which served as the companion diagnostic in the Phase 3 ADMIRAL trial resulting in approval of XOSPATA®.
- December 6, 2019
0
240
Less than a minute
You can share this post!
administrator
Related Articles
YB Ventures’ Core Company Celebrates 37 Years of…
- June 14, 2024
From Awareness To Action On Global Fatty Liver…
- June 14, 2024
AM Best Affirms Credit Ratings of Asian Reinsurance…
- June 14, 2024